MMRGlobal Adds Concierge Medicine Specialist Jeremy Fine, M.D. and Pediatrician and New York Times Best-Selling Author Cara

MMRGlobal Adds Concierge Medicine Specialist Jeremy Fine, M.D. and Pediatrician 
and New York Times Best-Selling Author Cara Natterson,
M.D. to Medical Board of Advisors 
LOS ANGELES, CA -- (Marketwired) -- 05/17/13 --  MMRGlobal, Inc.
(OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records
(PHRs) MyEsafeDepositBox storage solutions and MMRPro document
management and imaging systems for healthcare professionals, today
announced the addition of two new members to its Medical Board of
Advisors. Dr. Cara Natterson, M.D., a Board-Certified Pediatrician,
consultant and The New York Times best-selling author on child health
and parenting, will assist the Company with its plans to educate
parents on the importance of having a Personal Health Record for
their children as well as the best ways to offer PHR products and
services through pediatricians. Dr. Jeremy Fine, M.D. is a Concierge
Medicine Specialist and Board-Certified in Internal Medicine. Based
on his personal experience, Dr. Fine will assist the Company
educating Concierge Medicine professionals on the value of ensuring
that patients maintain an up-to-date PHR. The announcement was made
following MMRGlobal CEO Bob Lorsch's appearance on Fox News Radio in
a 30-minute interview on "The Vipp Jaswal Report." During the
interview, which is available at!/MMRGlobal?fref=ts, Lorsch discussed MMR's
business and how efforts in Washington to encourage steering a
portion of $27 billion in health IT stimulus to emerging growth
companies like MMR brought him and his wife Kira to spearhead a
humanitarian effort regarding the release of Dr. Shakil Afridi. 
Dr. Natterson has written five books, including "Worry Proof," winner
of the The Wall Street Journal's Best Health Book of the Year Award,
and authored the American Girl book, "The Care & Keeping of You 2."
She also updated American Girl's original "The Care & Keeping of
You," which has sold over three million copies. Dr. Fine has served
on the Executive Committee, Bioethics Committee and the Medical
Informatics Committee at Cedars-Sinai Medical Center. He is a former
Clinical Instructor of Medicine at both the UCLA and USC Schools of
Medicine and was chosen by Los Angeles Magazine as one of the Best
Doctors in Los Angeles.  
According to Lorsch, "Dr. Natterson and Dr. Fine will make a great
addition to the Company's Medical Board of Advisors, helping us
educate two specialty markets on the value of PHRs. Dr. Natterson's
role is to strategically introduce MyMedicalRecords to the pediatric
market in an effort to make both pediatricians and parents aware of
the importance of having a PHR for children at a very young age. Dr.
Jeremy Fine truly exemplifies what Concierge Medicine is all about
and being there for his patients whenever and wherever they need
Over the past several years, Dr. Fine routinely deployed
MyMedicalRecords accounts to his Concierge Medicine patients as part
of his Concierge Medicine protocol. "As a result, Dr. Fine knows
first-hand how valuable it can be in an emergency at 2 a.m. to have
the ability to log in to MyMedicalRecords and access a patient's
critical information regardless of where he or his patients are in
the world. Consumer awareness of the importance of having a PHR is
critical to the Company's business plan and there are no better
professionals than Drs. Natterson and Fine to carry our message to
physician colleagues, patients and parents," Lorsch added. 
Working with qualified healthcare professionals, including the
Company's medical advisers, MMR continues to focus on the deployment
of its Personal Health Record products and services and the licensing
of its patented technologies. MMRGlobal generates revenue from the
sale of Personal Health Records to employers for employee benefits,
direct to consumers, and patients. Through the MMR Stimulus Program,
physicians and hospitals that offer MyMedicalRecords PHRs to patients
can receive hundreds of thousands of dollars back from MMR as a
reimbursement for the costs of maintaining medical records.  
Following are brief biographies of the two new members of the Medical
Board Advisors: 
Dr. Jeremy Fine 
Dr. Fine completed his medical training in internal medicine at
Cedars-Sinai Medical Center in 2004 and was then selected to be Chief
Resident. He has served on the Executive Committee, Bioethics
Committee and the Medical Informatics Committee at Cedars-Sinai
Medical Center. He is also a former Clinical Instructor of Medicine
at both the UCLA and USC Schools of Medicine. He was chosen by Los
Angeles Magazine as one of the Best Doctors in Los Angeles and has
also been selected as one of California's Favorite Physicians. In
2010, he was voted Most Compassionate Doctor.  
Dr. Cara Natterson 
Dr. Natterson is a graduate of Harvard College and Johns Hopkins
School of Medicine, trained in pediatrics at the University of
California at San Francisco, and is a Board-Certified pediatrician
and a Fellow of the American Academy of Pediatrics. A former partner
at Tenth Street Pediatrics in Santa Monica, California, she now runs
Worry Proof Consulting, the first of its kind pediatric practice that
offers parents open-ended time to review everything from medical
questions and biology basics to child development and parenting
issues. Dr. Natterson appears on television, in print, and on the
web, and is a New York Times bestselling author, having written
several books on parenting and child health. Her most recent titles
were published in February 2013: "The Care and Keeping of You 1: The
Body Book for Younger Girls" and "The Care and Keeping of You 2: The
Body Book for Older Girls." Dr. Natterson's consulting includes
Fortune 500 companies seeking expert advice on child health, wellness
and safety issues. 
Members of the Company's Medical Board of Advisors also includes
Michel Babajanian, M.D., FAC., Board-Certified Otolaryngologist and
Head and Neck Surgeon; Glenn D. Braunstein, M.D., Vice President,
Clinical Innovation and Director of the Thyroid Cancer Center at
Cedars-Sinai Medical Center; David E. Bresler, PhD, LAc, Author,
Consultant and President, Academy for Guided Imagery; Shekhar Challa,
M.D., Board-Certified Gastroenterologist and Co-Founder and
President, Kansas Medical Clinic; Theodore B. Goldstein, M.D.,
Board-Certified Orthopedic Surgeon and Co-Medical Director,
Cedars-Sinai Spine Center; William H. Goodman, M.D., Pulmonary and
Critical Care Physician, Academic Appointment at Dartmouth Medical
School; Lawrence D. Piro, M.D., Clinician, International Expert in
Hematologic Malignancies, The Angeles Clinic and Research Institute;
David Charles Rish, M.D., Board-Certified Dermatologist; and Prediman
K. (PK) Shah, M.D., Director, Division of Cardiology and the
Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical
About MMRGlobal
 MMRGlobal, Inc., through its wholly-owned operating
subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use
online Personal Health Records ("PHRs") and electronic safe deposit
box storage solutions, serving consumers, healthcare professionals,
employers, insurance companies, financial institutions, retail
pharmacies, and professional organizations and affinity groups. The
MyMedicalRecords PHR enables individuals and families to access their
medical records and other important documents, such as birth
certificates, passports, insurance policies and wills, anytime from
anywhere using the Internet. MyMedicalRecords is built on
proprietary, patented technologies to allow documents, images and
voicemail messages to be transmitted and stored in the system using a
variety of methods, including fax, phone, or file upload without
relying on any specific electronic medical record platform to
populate a user's account. The Company's professional offering,
MMRPro, is designed to give physicians' offices an easy and
cost-effective solution to digitizing paper-based medical records and
sharing them with patients through an integrated patient portal.
Through its merger with Favrille, Inc. in January 2009, the Company
acquired intellectual property biotech assets that include anti-CD20
antibodies and data and samples from its FavId(TM)/Specifid(TM)
vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's
lymphoma. To learn more about MMRGlobal, Inc. visit View demos and video tutorials of the Company's
products and services at 
Forward-Looking Statements 
  All statements in this press release
that are not strictly historical in nature, including, without
limitation, the Company's future performance, management's
expectations, beliefs, intentions, estimates or projections,
constitute "forward-looking statements." Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the Company's actual results to be materially
different from historical results or from any results expressed or
implied by such forward-looking statements. Some can be identified by
the use of words (and their derivations) such as "need,"
"possibility," "potential," "intend," "offer," "development," "if,"
"negotiate," "when," "begun," "believe," "achieve," "will,"
"estimate," "expect," "maintain," "plan," and "continue," or the
negative of these words. Actual outcomes and results of operations
and the timing of selected events may differ materially from the
results predicted, and any reported results should not be considered
as an indication of future performance. Such statements are
necessarily based on assumptions and estimates and are subject to
various risks and uncertainties, including those relating to the
possible invalidity of the underlying assumptions and estimates and
possible changes or developments in economic, business, industry,
market, legal and regulatory circumstances and conditions and actions
taken or omitted to be taken by third parties, including customers,
suppliers, business partners, agents, potential licensees,
competitors and legislative, judicial and other governmental
authorities and officials. Factors that could cause or contribute to
such differences include, but are not limited to: unexpected outcomes
with respect to intellectual property enforcement actions, claims of
intellectual property infringement and general intellectual property
litigation; our ability to maintain, develop, monetize and protect
our patent portfolio for both the Company's health IT and
biotechnology intellectual property assets in the U.S. and
internationally; the timing of milestone payments in connection with
licensing our intellectual property; our ability to establish and
maintain strategic relationships; changes in our relationships with
our licensees; the risk the Company's products are not adopted or
viewed favorably by the healthcare community and consumer retail
market; business prospects, results of operations or financial
condition; risks related to the current uncertainty and instability
in financial and lending markets, including global economic
uncertainties; the timing and volume of sales and installations; the
length of sales cycles and the installation process; the market's
acceptance of new product and service introductions; programs and
initiatives, including the MMR Stimulus Program; competitive product
offerings and promotions; changes in government laws and regulations
and future changes in tax legislation and initiatives in the
healthcare industry both in the U.S. and internationally; undetected
errors in our products; the possibility of interruption at our data
centers; risks related to third party vendors; risks related to
obtaining and integrating third-party licensed technology; risks
related to a security breach by third parties; risks associated with
recruitment and retention of key personnel; other litigation matters;
uncertainties associated with doing business internationally across
borders and territories; and additional risks discussed in the
Company's filings with the Securities and Exchange Commission. The
Company is providing this information as of the date of this release
and, except as required by applicable law, does not undertake any
obligation to update any forward-looking statements contained in this
release as a result of new information, future events or otherwise.  
Michael Selsman
Public Communications Co.
(310) 922-7033 
Press spacebar to pause and continue. Press esc to stop.